Novo Nordisk expresses optimism on diabetes drug

11/16/2007 | Reuters

Novo Nordisk expressed confidence that its Type 2 diabetes drug liraglutide is as effective as Eli Lilly & Co.'s Byetta drug in treating the disease. The company is planning to bolster its U.S. sales force to promote its drug to general practitioners -- a move that could give the firm a competitive advantage over a long-acting version of Byetta, a Novo Nordisk official said at a health summit.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID